Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COSMOS Trial of AST-004 in complicated mild traumatic brain injury
NL-OMON61508Phase 2Not yet recruiting
- Sponsor
- Astrocyte Pharmaceuticals Inc.
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of AST-004 in traumatic brain injury (TBI), sponsored by Astrocyte Pharmaceuticals Inc. Primary endpoints: Safety through Day 7 and Change in plasma GFAP. Planned start May 2026; status: not yet recruiting.
02
Drugs
AST-004
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NL-OMON61508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61508.